NIH Reporter #5R01NS130876-03

NIH Grant for Genomic Technology Research in Multiple Sclerosis

This opportunity is a research grant offered by the National Institute of Neurological Disorders and Stroke (NINDS), part of the NIH, for a project focused on novel genomic technology in multiple sclerosis research. - Government Buyer: - National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH) - Primary Organization: - University of California, San Francisco - Products/Services Requested: - Research and development of SEARCH-seq, a novel genomic technology - High-throughput cytometry - Gene expression analysis - In vivo studies on rare astrocyte subsets in multiple sclerosis - Notable Requirements: - Focus on the XBP1 transcript and its role in MS pathology - Emphasis on regulatory mechanisms in rare pathogenic astrocyte subsets - No specific OEMs or commercial vendors are named, as this is a grant for academic research - Estimated grant value: $573,663 for the fiscal year - Project duration spans several years

Description

This NIH grant opportunity seeks to develop and apply a novel genomic technology called SEARCH-seq to study rare astrocyte subsets involved in multiple sclerosis. The project includes high-throughput cytometry, gene expression analysis, and in vivo studies focusing on the XBP1 transcript's role in MS pathology. The award amount is approximately $573,663 for fiscal year 2025, with a project duration from August 1, 2023, to July 31, 2028. The primary organization is the University of California, San Francisco, led by Dr. Adam R. Abate.

View original listing